Everest Medicines to Remove "B" Marker from Stock Code on May 2, 2025

April 28, 2025 | 08:00

(0) user say

The regulatory milestone signals Everest Medicines' growing financial maturity and market confidence.

SHANGHAI, April 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the "B" marker will cease to be affixed to the Company's stock short name, effective May 2, 2025. The removal of "B" marker was granted by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on April 22, 2025.

Everest Medicines was listed on the Stock Exchange in October 2020. Over the past three years, Everest has established and continuously deepened its "Dual-Engine" strategy. Evolving from an initial license-in model, the Company has developed a balanced approach that integrates in-house discovery with global partnerships and in-licensing, with a focus on high-value areas and the development of first-in-class or best-in-class assets. With global rights to EVER001, the Company will actively explore partnership opportunities to leverage international expertise and optimize commercial value, while further enhancing its global visibility and market presence. Everest will utilize its efficient commercial platform to solidify its leadership in key therapeutic areas, advance innovation on its mRNA platform, and strive to become a leading biopharma in the Asia-Pacific region by 2030.

For more information, please visit its website at www.everestmedicines.com.

By PR Newswire

Everest Medicines

What the stars mean:

★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional